TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX ) (OTCQB: NRXBF ) (FSE: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, is pleased to announce that a patent covering the "Production of extracellular vesicles from stem cells" has been granted by IP Australia. The patent, Australian Patent No. 2020303456, was granted on April 23, 2026 and is held by Technion Research and Development Foundation Limited. The patent relates to technology licensed exclusively to NurExone and is expected to remain in force until June 10, 2040, subject to the payment of applicable fees. "Consistency is one of the most important value drivers in biomanufacturing," said Dr. Lior Shaltiel, CEO of NurExone. "This patent grant supports our strategy to protect core technologies enabling the scalable, reproducible production of high-quality exosomes required for therapeutic development. As we take steps to build manufacturing capacity, including our recently announced LOI with U.S.-based BioXtek , we are also working in parallel to protect the technologies to support scalable and reliable exosome production." The patent further expands NurExone's international patent family covering the production of extracellular vesicles from stem cells. It follows previously announced patent grants in Israel and the United States, with additional applications currently under examination in other jurisdictions. This development reflects the Company's strategy to secure broad, strategically aligned intellectual property protection across key commercial, regulatory, and manufacturing markets in support of its exosome biomanufacturing technology. Scientific Presentation on ExoPTEN's Regenerative Potential in Optic Nerve Damage The use of NurExone's ExoPTEN in models of damaged optic nerves will be featured in an upcoming scientific presentation by Dr. Ifat Sher and Prof. Ygal Rotenstreich of the Goldschleger Eye Institute ... Full story available on Benzinga.com
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
